Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents

Atherosclerosis

Volumn 189, Issue 2, 2006, Pages 401-407

  Gilardini, Luisa ^a   McTernan, Philip G ^b   Girola, Andrea ^a   da Silva, Nancy F ^b   Alberti, Luisella ^a   Kumar, Sudhesh ^b   Invitti, Cecilia ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Adiponectin; Metabolic syndrome; Obese children; PAI 1; Uric acid

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; INSULIN; INTERLEUKIN 18 BINDING PROTEIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; URIC ACID;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CIRCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PARAMETERS OF MEASUREMENT AND ANALYSIS; PEDIATRICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; URIC ACID BLOOD LEVEL;

ADIPONECTIN; ADOLESCENT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHILD; FEMALE; HUMANS; INSULIN; INTERLEUKIN-8; ITALY; MALE; METABOLIC SYNDROME X; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; URIC ACID;

EID: 33750325774     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.12.021     Document Type: Article

References (46)

1. Lobstein T., Baur L., and Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev 5 Suppl. 1 (2004) 4-104
2. Duncan G.E., Li S.M., and Zhou X.H. Prevalence and trends of a metabolic syndrome phenotype among U.S. adolescents, 1999-2000. Diabetes Care 27 (2004) 2438-2443
3. Invitti C, Maffeis C, Gilardini L, et al. Metabolic syndrome and non traditional cardiovascular risk factors in obese Caucasian children. Int J Obes 2006;30; in press.
4. Dandona P., Alijada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
5. Ryo M., Nakamura T., Kihara S., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004) 975-981
6. Lau D.C., Dhillon B., Yan H., Szmitko P.E., and Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288 5 (2005) 2031-2041
7. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
8. Alessi M.C., Lijnen H.R., Bastelica D., and Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 33 (2004) 290-297
9. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 1131-1137
10. Elhage R., Jawien J., Rudling M., et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 59 (2003) 234-240
11. Esposito K., Pontillo A., Ciotola M., et al. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87 (2002) 3864-3866
12. Blankenberg S., Tiret L., Bickel C., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106 (2002) 24-30
13. Janoskuti L., Forhecz Z., Hosszufalusi N., et al. High levels of C-reactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease. Eur J Clin Invest 35 (2005) 104-111
14. Nystrom T., Nygren A., and Sjoholm A. Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clin Sci 108 (2005) 121-128
15. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14 (2003) 561-566
16. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
17. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167
18. Schulze M.B., Shai I., Rimm E.B., et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
19. Engeli S., Feldpausch M., Gorzelniak K., et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52 (2003) 942-947
20. Choi K.M., Lee J., Lee K.W., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol 61 (2004) 75-80
21. Ogawa Y., Kikuchi T., Nagasaki K., et al. Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens Res 28 (2005) 51-57
22. Mohan V., Deepa R., Pradeepa R., et al. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 54 (2005) 476-481
23. Moran A., Steffen L.M., Jacobs D.R., et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 28 (2005) 1763-1768
24. Sudi K., Gallistl S., Payerl D., et al. Interrelationship between estimates of adiposity and body fat distribution with metabolic and hemostatic parameters in obese children. Metabolism 50 (2001) 681-687
25. Stefan N., Bunt J.C., Salbe A.D., et al. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 87 (2002) 4652-4656
26. Bacha F., Saad R., Gungor N., and Arslanian S.A. Adiponectin in youth. Diabetes Care 27 (2004) 547-552
27. Weiss R., Dziura J., Burgert T.S., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 (2004) 2362-2374
28. Valle M., Martos R., Gascon F., et al. Low-grade systemic inflammation, hypoadiponectinemia, and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes 31 (2005) 55-62
29. Bottner A., Kratzsch J., Muller G., et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 89 (2004) 4053-4061
30. Cacciari E., Milani S., Balsamo A., et al. Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 56 (2002) 171-180
31. World Health Organization Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Geneva, World Health Organization 1999.
32. Tanner J.M. Growth and maturation during adolescence. Nutr Rev 39 (1998) 43-55
33. Matthews D.R., Hosker J.P., and Rudenski A.S. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
34. Invitti C., Guzzaloni G., Gilardini L., Morabito F., and Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care 26 (2003) 118-124
35. Cole T.J., Bellizzi M.C., Flegal K.M., and Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320 (2000) 1240-1243
36. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 21 Suppl. 1 (2004) II2-II10
37. Butte N.F., Comuzzie A.G., Cai G., et al. Genetic and environmental factors influencing fasting serum adiponectin in Hispanic children. J Clin Endocrinol Metab 90 (2005) 4170-4176
38. Kumada M., Kihara S., Sumitsuji S., et al., Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
39. Xu A., Chan K.W., Hoo R.L., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280 (2005) 18073-18080
40. Bush N.C., Darnell B.E., Oster R.A., Goran M.I., and Gower B.A. Adiponectin is lower among African Americans and is independently related to insulin sensitivity in children and adolescents. Diabetes 54 (2005) 2772-2778
41. Abate N., Chandalia M., Snell P.G., and Grundy S.M. Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. J Clin Endocrinol Metab 89 (2004) 2750-2755
42. Maruyoshi H., Kojima S., Funahashi T., et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 91 (2004) 1026-1230
43. Ma L.J., Mao S.L., Taylor K.L., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
44. Madsen T.E., Muhlestein J.B., Carlquist J.F., et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 25 (2005) 45-49
45. Chien K.L., Hsu H.C., Sung F.C., et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 183 (2005) 147-155
46. Han T.S., Sattar N., Williams K., et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (2002) 2016-2021